
Advanced Enzyme Technologies: Technical Momentum Shifts Amid Mixed Market Signals
2025-12-02 08:10:24Advanced Enzyme Technologies has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. This change is underscored by a combination of technical indicators reflecting contrasting signals across weekly and monthly timeframes, suggesting a complex market assessment for the pharmaceutical and biotechnology company.
Read MoreWhy is Advanced Enzyme falling/rising?
2025-11-25 01:18:19Recent Price Movement and Market Context The stock has been under pressure for the past five consecutive trading sessions, accumulating a loss of 7.17% over the week. This decline is notably sharper than the marginal 0.06% drop in the Sensex during the same period, indicating company-specific factors influencing investor sentiment. Intraday, the stock touched a low of ₹309.95, marking a 2.22% dip from its previous close. While the broader chemicals sector fell by 2.07%, Advanced Enzyme marginally outperformed its sector peers today by 0.69%, suggesting some resilience amid sector-wide weakness. Technically, the stock price remains above its 200-day moving average, a long-term support indicator, but is trading below its short- and medium-term averages including the 5-da...
Read More
Advanced Enzyme Technologies: Analytical Perspective Shift Amid Mixed Financial and Technical Signals
2025-11-24 08:08:27Advanced Enzyme Technologies has experienced a revision in its market assessment following a detailed review of its quality, valuation, financial trends, and technical indicators. Despite some positive quarterly financial results, the company’s long-term growth trajectory and technical signals present a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector.
Read More
Advanced Enzyme Technologies Faces Mixed Technical Signals Amid Price Momentum Shift
2025-11-24 08:05:16Advanced Enzyme Technologies has experienced a notable shift in its price momentum and technical indicators, reflecting a complex market assessment. The stock’s recent movement reveals a transition from a mildly bullish trend to a sideways pattern, with key technical signals presenting a blend of bearish and bullish cues across different timeframes.
Read MoreHow has been the historical performance of Advanced Enzyme?
2025-11-21 22:47:20Revenue and Profit Growth Trajectory Advanced Enzyme’s net sales have shown a robust upward trend, rising from ₹419.59 crores in March 2019 to ₹636.91 crores by March 2025. This represents a compound growth trajectory reflecting the company’s expanding market presence and operational scale. Total operating income mirrored this growth, with no other operating income reported during this period, indicating core business activities as the primary revenue source. Profitability metrics reveal a nuanced picture. Operating profit before other income (PBDIT excl OI) peaked at ₹231.61 crores in March 2021 but moderated to ₹194.44 crores by March 2025. Including other income, operating profit (PBDIT) followed a similar pattern, reaching ₹240.46 crores in 2021 before settling at ...
Read More
Advanced Enzyme Technologies Reports Strong Sales Growth Amid Long-Term Profit Challenges
2025-11-13 08:20:00Advanced Enzyme Technologies has recently adjusted its evaluation, reflecting a shift in its stock's technical landscape. The company reported a 26.30% increase in net sales for Q2 FY25-26, alongside strong operating cash flow and PBDIT figures. However, it faces long-term growth challenges, with a slight decline in annual operating profit over five years.
Read MoreIs Advanced Enzyme technically bullish or bearish?
2025-11-13 08:14:54As of 12 November 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating bullish momentum. However, the weekly MACD and KST are bearish, which suggests caution. The monthly RSI shows bullishness, but the overall monthly indicators, including Bollinger Bands and Dow Theory, are mildly bearish. The mixed signals across different time frames indicate a complex situation, but the recent trend change and daily bullish indicators support a mildly bullish outlook....
Read More
Advanced Enzyme Technologies Faces Mixed Technical Trends Amid Market Evaluation Revision
2025-11-13 08:09:43Advanced Enzyme Technologies, a small-cap firm in the Pharmaceuticals and Biotechnology sector, has recently revised its evaluation amid changing market conditions. The stock has shown a notable weekly return, outperforming the Sensex, while technical indicators present a mixed outlook, reflecting both bullish and bearish trends across different time frames.
Read MoreHow has been the historical performance of Advanced Enzyme?
2025-11-13 00:25:12Answer: The historical performance of Advanced Enzyme shows a steady growth in net sales and profits over the years, with some fluctuations in specific metrics. Breakdown: Advanced Enzyme's net sales increased from 419.59 Cr in March 2019 to 636.91 Cr in March 2025, reflecting a consistent upward trend. Total operating income followed a similar trajectory, rising from 419.59 Cr in March 2019 to 636.91 Cr in March 2025. However, total expenditure also grew, reaching 442.47 Cr in March 2025, up from 237.67 Cr in March 2019. Operating profit (PBDIT) peaked at 240.46 Cr in March 2021 but saw a decline to 227.48 Cr by March 2025. Profit before tax showed some variability, with a high of 210.13 Cr in March 2021 and a slight decrease to 187.36 Cr in March 2025. Profit after tax was 133.97 Cr in March 2025, down from 151.29 Cr in March 2021. The company's total assets grew from 971.18 Cr in March 2020 to 1,611.15 ...
Read MoreAnnouncement under Regulation 30 (LODR)-Investor Presentation
31-Jan-2026 | Source : BSEEarnings Presentation for the quarter and nine months ended December 31 2025
Update On The Judicial Proceedings Against Advanced Supplementary Technologies Corporation USA (Step Down Wholly Owned Subsidiary) [AST]
31-Jan-2026 | Source : BSEThis has reference to our earlier intimation dated February 28 2024 regarding the lawsuit filed by World Nutrition Inc. against Advanced Supplementary Technologies Corporation USA a step-down wholly owned subsidiary of the Company before the District Court of Arizona (USA)
Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter And Nine Months Ended December 31 2025
31-Jan-2026 | Source : BSEAdvanced Enzyme Technologies Limited has informed the Exchange about the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended December 31 2025
Corporate Actions
No Upcoming Board Meetings
Advanced Enzyme Technologies Ltd has declared 60% dividend, ex-date: 23 Jul 25
Advanced Enzyme Technologies Ltd has announced 2:10 stock split, ex-date: 25 May 17
No Bonus history available
No Rights history available